185 related articles for article (PubMed ID: 31211434)
1. Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study.
Perry C; Ben Barouch S; Goldschmidt N; Sarid N; Herishanu Y; Shvidel L; Bairey O; Lavi N; Horowitz N; Avigdor A; Lebel E; Sofer O; Ram R; Avivi I
Am J Hematol; 2019 Sep; 94(9):992-1001. PubMed ID: 31211434
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance.
Wight JC; Yue M; Keane C; Johnston A; Linton K; Chin C; Wai SH; Talaulikar D; Gasiorowski R; Cheah CY; Gregory GP; Dickinson M; Minson A; Coombes C; Ku M; Lam S; Hawkes EA
Br J Haematol; 2019 Oct; 187(2):174-184. PubMed ID: 31236941
[TBL] [Abstract][Full Text] [Related]
3. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
4. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma.
Arkenau HT; Chong G; Cunningham D; Watkins D; Agarwal R; Sirohi B; Trumper M; Norman A; Wotherspoon A; Horwich A
Ann Oncol; 2007 Mar; 18(3):541-5. PubMed ID: 17164228
[TBL] [Abstract][Full Text] [Related]
5. Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma.
Kim SJ; Oh SY; Kim JS; Kim H; Lee GW; Won JH; Shin HJ; Yang DH; Choi CW; Park J; Kim WS; Suh C
Ann Hematol; 2011 May; 90(5):539-46. PubMed ID: 20960190
[TBL] [Abstract][Full Text] [Related]
6. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.
El-Galaly TC; Cheah CY; Bendtsen MD; Nowakowski GS; Kansara R; Savage KJ; Connors JM; Sehn LH; Goldschmidt N; Shaulov A; Farooq U; Link BK; Ferreri AJM; Calimeri T; Cecchetti C; Dann EJ; Thompson CA; Inbar T; Maurer MJ; Gade IL; Juul MB; Hansen JW; Holmberg S; Larsen TS; Cordua S; Mikhaeel NG; Hutchings M; Seymour JF; Clausen MR; Smith D; Opat S; Gilbertson M; Thanarajasingam G; Villa D
Eur J Cancer; 2018 Apr; 93():57-68. PubMed ID: 29477102
[TBL] [Abstract][Full Text] [Related]
7. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
8. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
9. Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy.
Bokstein F; Lossos A; Lossos IS; Siegal T
Leuk Lymphoma; 2002 Mar; 43(3):587-93. PubMed ID: 12002763
[TBL] [Abstract][Full Text] [Related]
10. Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network.
Damaj G; Ivanoff S; Coso D; Ysaebert L; Choquet S; Houillier C; Parcelier A; Abarah W; Marjanovic Z; Gressin R; Garidi R; Diouf M; Gac AC; Dupuis J; Troussard X; Morschhauseur F; Ghesquières H; Soussain C;
Haematologica; 2015 Sep; 100(9):1199-206. PubMed ID: 26185174
[TBL] [Abstract][Full Text] [Related]
11. Diffuse large B-cell lymphoma at risk of secondary CNS involvement: The inefficacy of intravenous high-dose methotrexate CNS prophylaxis and the importance of baseline cerebrospinal fluid analysis.
Bennett R; Ruskova A; Coomarasamy C; Theakston E; Berkahn L; Jackson S; Christophers M; Wong S; Issa S
Am J Hematol; 2023 Jul; 98(7):1070-1079. PubMed ID: 37161765
[TBL] [Abstract][Full Text] [Related]
12. Pilot trial of systemic methotrexate plus R-CHOP regimen with intrathecal methotrexate for simultaneous central nervous system and systemic diffuse large B cell lymphoma.
Yoo KH; Lee JY; Lim SH; Ko YH; Kim SJ; Kim WS
Acta Haematol; 2015; 133(2):179-82. PubMed ID: 25323539
[TBL] [Abstract][Full Text] [Related]
13. Systemic HD-MTX for CNS prophylaxis in high-risk DLBCL patients: a prospectively collected, single-center cohort analysis.
Lee K; Yoon DH; Hong JY; Kim S; Lee K; Kang EH; Huh J; Park CS; Lee SW; Suh C
Int J Hematol; 2019 Jul; 110(1):86-94. PubMed ID: 31115880
[TBL] [Abstract][Full Text] [Related]
14. Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.
Tomita N; Takasaki H; Ishiyama Y; Kishimoto K; Ishibashi D; Koyama S; Ishii Y; Takahashi H; Numata A; Watanabe R; Tachibana T; Ohshima R; Hagihara M; Hashimoto C; Takemura S; Taguchi J; Fujimaki K; Sakai R; Motomura S; Ishigatsubo Y
Leuk Lymphoma; 2015 Mar; 56(3):725-9. PubMed ID: 24913502
[TBL] [Abstract][Full Text] [Related]
15. Comparison of standardized prophylactic high-dose and intrathecal methotrexate for DLBCL with a high risk of CNS relapse.
Akimoto M; Miyazaki T; Takahashi H; Saigusa Y; Takeda T; Hibino Y; Tokunaga M; Ohashi T; Matsumura A; Teshigawara H; Suzuki T; Teranaka H; Nakajima Y; Matsumoto K; Hashimoto C; Fujimaki K; Fujita H; Sakai R; Fujisawa S; Nakajima H
Int J Hematol; 2024 Feb; 119(2):164-172. PubMed ID: 38233702
[TBL] [Abstract][Full Text] [Related]
16. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
Abramson JS; Hellmann M; Barnes JA; Hammerman P; Toomey C; Takvorian T; Muzikansky A; Hochberg EP
Cancer; 2010 Sep; 116(18):4283-90. PubMed ID: 20564149
[TBL] [Abstract][Full Text] [Related]
17. Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers.
Jurczak W; Kroll-Balcerzak R; Giebel S; Machaczka M; Giza A; Ogórka T; Fornagiel S; Rybka J; Wróbel T; Kumiega B; Skotnicki AB; Komarnicki M
Med Oncol; 2015 Apr; 32(4):90. PubMed ID: 25716885
[TBL] [Abstract][Full Text] [Related]
18. Impact of contemporary regimens on the outcomes and toxicity of primary CNS lymphoma: a single-center retrospective analysis of 73 patients.
Sarid N; Bokstein F; Blumenthal DT; Weiss-Meilik A; Gibstein L; Avivi I; Perry C; Ram R
J Neurooncol; 2021 Jan; 151(2):211-220. PubMed ID: 33099747
[TBL] [Abstract][Full Text] [Related]
19. Optimization of high-dose methotrexate prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma: a multicenter analysis.
Fang Y; Su N; Ma S; Cai J; Zhong L; Li W; Huang H; Li Z; Huang H; Xia Y; Liu P; Guo L; Li Z; Wu Y; Tian X; Wang J; Zhang Y; Cai Q
Ann Hematol; 2022 Mar; 101(3):595-605. PubMed ID: 34985557
[TBL] [Abstract][Full Text] [Related]
20. Intravenous but not intrathecal central nervous system-directed chemotherapy improves survival in patients with testicular diffuse large B-cell lymphoma.
Mannisto S; Vähämurto P; Pollari M; Clausen MR; Jyrkkiö S; Kellokumpu-Lehtinen PL; Kovanen P; Karjalainen-Lindsberg ML; d'Amore F; Leppä S
Eur J Cancer; 2019 Jul; 115():27-36. PubMed ID: 31082690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
